Get the Stockscreener App
5.50
0.36%
0.02
After Hours:
5.46
-0.04
-0.73%
Siga Technologies Inc stock is traded at $5.50, with a volume of 352.85K.
It is up +0.36% in the last 24 hours and up +0.18% over the past month.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
See More
Previous Close:
$5.48
Open:
$5.39
24h Volume:
352.85K
Relative Volume:
0.86
Market Cap:
$391.47M
Revenue:
$172.96M
Net Income/Loss:
$83.97M
P/E Ratio:
4.7009
EPS:
1.17
Net Cash Flow:
$73.77M
1W Performance:
-4.01%
1M Performance:
+0.18%
6M Performance:
-20.52%
1Y Performance:
-43.01%
1-Day Range:
$5.36
$5.505
1-Week Range:
$5.36
$5.76
52-Week Range:
$5.27
$12.83
Siga Technologies Inc Stock (SIGA) Company Profile
Name
Siga Technologies Inc
Sector
Phone
212-672-9100
Address
31 EAST 62ND STREET, NEW YORK, NY
Compare SIGA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SIGA
Siga Technologies Inc
|
5.50 | 391.47M | 172.96M | 83.97M | 73.77M | 1.17 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Siga Technologies Inc Stock (SIGA) Latest News
Could The Market Be Wrong About SIGA Technologies, Inc. (NASDAQ:SIGA) Given Its Attractive Financial Prospects? - Yahoo Finance
AltraVue Capital LLC Buys 326,630 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA) - MarketBeat
Brokers Issue Forecasts for SIGA FY2025 Earnings - MarketBeat
Siga Technologies Inc. (SIGA) Stock Sinks As Market Gains: What You Should Know - MSN
Government Contract Update: $26M payment to SIGA TECHNOLOGIES, INC - Nasdaq
Charles Schwab Investment Management Inc. Decreases Stake in SIGA Technologies, Inc. (NASDAQ:SIGA) - MarketBeat
Global Monkeypox Vaccine MarketCompanies & Government - openPR.com
Bank of New York Mellon Corp Boosts Stock Holdings in SIGA Technologies, Inc. (NASDAQ:SIGA) - MarketBeat
(SIGA) Long Term Investment Analysis - Stock Traders Daily
SIGA Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA) - MarketBeat
Siga Technologies Inc. (SIGA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Vestcor Inc Invests $290,000 in SIGA Technologies, Inc. (NASDAQ:SIGA) - MarketBeat
Siga Technologies Inc. (SIGA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
SIGA Technologies, Inc. (NASDAQ:SIGA) Sees Significant Growth in Short Interest - MarketBeat
SIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Victory Capital Management Inc. - MarketBeat
SIGA Technologies adds Retired General to Board By Investing.com - Investing.com Australia
Entering a crucial period for business outlook - Research Tree
SIGA Appoints John M. Keane To Board - citybiz
SIGA Technologies appoints General Keane to Board By Investing.com - Investing.com Canada
SIGA Technologies adds Retired General to Board - Investing.com
SIGA Technologies appoints General Keane to Board - Investing.com
SIGA Technologies Appoints Gen. Keane as New Director - TipRanks
SIGA Appoints Retired General John M. Keane to its Board of Directors - GlobeNewswire
Siga Technologies Inc. (SIGA) Rises Higher Than Market: Key Facts - Yahoo Finance
SIGA Technologies (NASDAQ:SIGA) Posts Quarterly Earnings Results - MarketBeat
Ashton Thomas Private Wealth LLC Acquires New Holdings in SIGA Technologies, Inc. (NASDAQ:SIGA) - MarketBeat
NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox - Benzinga
NIH Says Tecovirimat Is Safe But Ineffective As Treatment For Clade II Mpox -March 12, 2025 at 01:08 pm EDT - Marketscreener.com
NIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II Mpox - TipRanks
SIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2024 Earnings Call Transcript - Insider Monkey
SIGA Technologies Inc (SIGA) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo
SIGA Technologies reports Q4 revenue of $81.4 million, stock edges up - Investing.com Australia
SIGA Technologies Inc (SIGA) Q4 2024 Earnings Call Highlights: S - GuruFocus.com
SIGA Technologies Reports Strong 2024 Financial Performance - TipRanks
Earnings call transcript: SIGA Technologies Q4 2024 sees modest growth By Investing.com - Investing.com Canada
Earnings call transcript: SIGA Technologies Q4 2024 sees modest growth - Investing.com
SIGA TECHNOLOGIES INC SEC 10-K Report - TradingView
SIGA Technologies Q4 Earnings, Revenue Fall -March 11, 2025 at 04:42 pm EDT - Marketscreener.com
SIGA Technologies reports Q4 revenue of $81.4 million, stock edges up By Investing.com - Investing.com South Africa
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 - The Manila Times
Siga Technologies Inc Stock (SIGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):